UBS Group’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

UBS Group’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-22,218	Closed	-$90K	–	10390
2023 Q4	$90K	Buy	22,218 +11,468	+107%	+$35K	﹤0.01%	6228
2023 Q3	$28.9K	Buy	10,750 +6,520	+154%	+$25.6K	﹤0.01%	6606
2023 Q2	$39.5K	Sell	4,230 -2,621	-38%	-$25.8K	﹤0.01%	6592
2023 Q1	$60.8K	Buy	6,851 +2,207	+48%	+$21.7K	﹤0.01%	6298
2022 Q4	$23.1K	Buy	+4,644	New	+$27.2K	﹤0.01%	7499
2022 Q2	–	Sell	-2,041	Closed	-$24K	–	11254
2022 Q1	$24K	Sell	2,041 -1,527	-43%	-$16.3K	﹤0.01%	7263
2021 Q4	$45K	Buy	+3,568	New	+$53.9K	﹤0.01%	7014

UBS Group's THRX Position: Q1 2024 in Review

UBS Group sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 22,218 shares — an estimated $90K sold.

UBS Group first reported a position in THRX in Q4 2021 and held it in 7 quarters. The position peaked at $90K in Q4 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

UBS Group reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
UBS Group sold 22,218 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $90K.
UBS Group first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
UBS Group's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $90K in Q4 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.